University of Patras
Διερεύνηση του επιγενετικού μηχανισμού επανέκφρασης της εμβρυϊκής αιμοσφαιρίνης (HbF) σε ασθενείς με μυελοδυσπλαστικό σύνδρομο (MDS) μετά από θεραπεία με απομεθυλιωτικό παράγοντα και αναζήτηση της προγνωστικής σημασίας της επανέκφρασης αυτής για την ανταπόκριση στη θεραπεία των ασθενών
Abstract
dc:descriptionBackground : myelodysplastic syndromes (MDS) are characterized by epigenetic modification and dysregulation, and hypomethylating agents (HMAs), decitabine (DAC) and azacytidine (AZA), remain the primary therapeutic options to prevent the progression of high-risk MDS (HR-MDS) patients, to acute myeloid leukemia (AML). Although the mechanism of action of HMAs has been extensively studied, it remains yet incompletely understood. As new treatment options emerge for patients with HR-MDS, the identification of accessible prognostic markers for the response to HMA therapy and the understanding of mechanisms, underlying their delayed and short-term responses are essential. Despite their known action against DNMT1 and DNMT3A methyltransferases, uncertainty persists regarding the prognostic value of induced hypomethylation. Data from studies on peripheral blood cells suggest that after initial hypomethylation, DNA methylation levels are restored by the end of the 28-day treatment cycle with HMAs. However, data on DNA methylation analysis from bone marrow aspirates of MDS patients using high-resolution advanced techniques are scarce in the literature. Since it is epigenetically silenced, fetal hemoglobin (HbF) induction has been proposed as a prognostic marker for patients receiving DAC. Furthermore, although epigenetic mechanisms are assumed, the methylomes of patients have not been thoroughly examined to elucidate the precise mechanism of HbF re-expression. Our aim was to clarify the kinetics and prognostic value of HbF in patients undergoing AZA treatment. Additionally, we investigated the changes in the epigenetic landscape of patients treated with HMAs at the genome-wide/chromosomal level, as well as the alterations in the methylation of HbF expression regulators following AZA treatment and their clinical significance. Results: In the cohort of patients treated with HMAs and analyzed using genome-wide methylated DNA sequencing (MeD-seq) with the restriction enzyme LpnPI (n=13), an overall increase in average chromosomal methylation was observed, along with a concurrent relative decrease in specific regions, primarily involving non-coding RNAs, among responders (n=6) at the end of six or more HMA treatment cycles. In contrast, non-responders (n=7) exhibited hypomethylation across most chromosomes, which did not lead to an improvement in their clinical phenotype but might instead, have promoted disease progression, as seen in other cancer types. However, chromosomes 21, X, and Y were notably hypermethylated. Serial HbF measurements using high-performance liquid chromatography (n=20) showed HbF induction only among AZA responders (p=0.030). Furthermore, HbF increase immediately after the first AZA treatment cycle demonstrated prognostic value for progression-free survival (PFS) (p=0.032, HR=0.19, CI:0.24-1.63). In AZA-treated patients, changes in methylation patterns were revealed through MeD-seq analysis (n=7) for the genes FOG-1, RCOR-1, ZBTB7A, and genes encoding subunits of the NuRD complex. Targeted pyrosequencing methodology (n=28) revealed a strong inverse correlation between the methylation status of the γ-globin gene (HBG2) promoter and baseline HbF levels (p=0.003, rs=-0.663). A potential epigenetic mechanism of HbF re-expression in AZA responders was highlighted by targeted methylation analysis, showing hypomethylation of the -53 site of the HBG2 promoter (p=0.039, rs=-0.504), which corresponds to the MBD2-NuRD binding site, as well as hypermethylation of the CpG326 island of ZBTB7A (p=0.05, rs=0.482); a known HbF repressor. These changes were associated with blast cell clearance in the bone marrow (pHBG2=0.011, rs=0.480 / pZBTB7A=0.026, rs=0.427) and demonstrated prognostic value for PFS (pZBTB7A=0.037, HR=1.14, CI:0.34-3.8). Reduction of ZBTB7A expression in leukemic cell lines (TF1, MV4-11) showed a tendency to decrease their proliferation, although without a reduction in clonogenicity or sensitivity to AZA. Treatment with low-dose AZA in differentiating to erythroid TF1 cells did indeed show an increase in HBG2 expression along with a simultaneous decrease in ZBTB7A. Conclusions: Response to HMAs appears to be associated with patterns of average hypermethylation at the chromosomal level after at least six treatment cycles, with their demethylating effect targeting specific genomic regions, including non-coding RNAs. In contrast, overall hypomethylation is observed in non-responding patients across most chromosomes, except for chromosomes 21, X, and Y, which are strongly hypermethylated. Early HbF induction emerges as an accessible prognostic marker for HMA therapy, and the proposed epigenetic mechanism of HbF re-expression in AZA responders involves hypomethylation of the γ-globin gene promoter and hypermethylation of the CpG326 regulatory island of ZBTB7A. The correlation of these methylation patterns with blast cell clearance and their prognostic value for PFS, along with the chromosomal-level methylation changes based on treatment response, pave the way for a deeper exploration of the epigenetic mechanism of action of HMAs.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Chatzilygeroudi, Theodora
- Χατζηλυγερούδη, Θεοδώρα
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/57877